Which groups are specifically contraindicated for Avonib/Tosovo?

Although Ivosidenib is a targeted therapy drug with high selectivity and tolerability, it is not suitable for all patients. In clinical use, clarifying contraindication groups is an important step in ensuring drug safety and efficacy. First of all, patients who are known to be allergic to ivonib or drug excipients should be strictly prohibited from using it to prevent severe allergic reactions or infusion-related adverse events. Drug allergies may manifest as rash, difficulty breathing, or angioedema, and in severe cases may be life-threatening.

Secondly, pregnant women and lactating women are usually classified as contraindications. Ivonib may cause potential harm to the fetus or infant, so female patients must take effective contraceptive measures during and within a certain period of time after treatment to avoid pregnancy. At the same time, lactating women should suspend breastfeeding to prevent the drug from affecting the baby's health through milk.

In addition, ivosidenib is contraindicated in patients with severe hepatic impairment or active severe liver disease. Since the drug is mainly metabolized by the liver, abnormal liver function may lead to elevated blood drug concentrations and increase the risk of adverse reactions, including hepatotoxicity and QT interval prolongation. Use with caution or avoidance in patients with severe cardiovascular disease, cardiac arrhythmias, or QT prolongation to reduce the risk of cardiac events.

For children or minors, there is currently a lack of sufficient safety and efficacy data, so its use is generally not recommended unless guided by strict clinical trials. At the same time, patients with severe myelosuppression or major infection risks need to be used with caution after evaluation to avoid exacerbation of hematological toxicity.

In general, contraindications for ivonib include people with drug allergies, pregnant and lactating women, patients with severe liver damage, patients with severe cardiovascular disease, and minors or those with extremely low bone marrow function. Before use, doctors need to comprehensively evaluate the patient's past medical history, laboratory indicators and concomitant medications to ensure the safety of the medication and maximize the precise efficacy of ivonib in the treatment of IDH1 mutant tumors.

Reference: https://www.tibsovo.com/